

# Umberto Tosi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7586686/publications.pdf>

Version: 2024-02-01

35  
papers

420  
citations

840585

11  
h-index

794469

19  
g-index

35  
all docs

35  
docs citations

35  
times ranked

636  
citing authors

#	ARTICLE	IF	CITATIONS
1	FosB Regulates Gene Expression and Cognitive Dysfunction in a Mouse Model of Alzheimer's Disease. Cell Reports, 2017, 20, 344-355.	2.9	85
2	Early Seizure Activity Accelerates Depletion of Hippocampal Neural Stem Cells and Impairs Spatial Discrimination in an Alzheimer's Disease Model. Cell Reports, 2019, 27, 3741-3751.e4.	2.9	51
3	Transcriptome signatures associated with meningioma progression. Acta Neuropathologica Communications, 2019, 7, 67.	2.4	36
4	B7-1 as a Prognostic Biomarker and Therapeutic Target in Pediatric central nervous system Tumors. Translational Oncology, 2020, 13, 365-371.	1.7	33
5	Real-Time, <i>in Vivo</i> Correlation of Molecular Structure with Drug Distribution in the Brain Striatum Following Convection Enhanced Delivery. ACS Chemical Neuroscience, 2019, 10, 2287-2298.	1.7	25
6	<sup>18</sup> F-Radiolabeled Panobinostat Allows for Positron Emission Tomography Guided Delivery of a Histone Deacetylase Inhibitor. ACS Medicinal Chemistry Letters, 2018, 9, 114-119.	1.3	21
7	PET, image-guided HDAC inhibition of pediatric diffuse midline glioma improves survival in murine models. Science Advances, 2020, 6, eabb4105.	4.7	21
8	Convection Enhanced Delivery for Diffuse Intrinsic Pontine Glioma: Review of a Single Institution Experience. Pharmaceutics, 2020, 12, 660.	2.0	16
9	A Murine Model for Quantitative, Real-Time Evaluation of Convection-Enhanced Delivery (RT-CED) Using an <sup>18</sup> F-Positron Emitting, Fluorescent Derivative of Dasatinib. Molecular Cancer Therapeutics, 2017, 16, 2902-2912.	1.9	15
10	Advances in Molecular Imaging of Locally Delivered Targeted Therapeutics for Central Nervous System Tumors. International Journal of Molecular Sciences, 2017, 18, 351.	1.8	15
11	Ventrolateral Tonsillar Position Defines Novel Chiari 0.5 Classification. World Neurosurgery, 2020, 136, 444-453.	0.7	14
12	Stereotactic radiosurgery for vestibular schwannomas in neurofibromatosis type 2 patients: a systematic review and meta-analysis. Journal of Neuro-Oncology, 2022, 156, 431-441.	1.4	11
13	Persistent Syringomyelia After Posterior Fossa Decompression for Chiari Malformation. World Neurosurgery, 2020, 136, 454-461.e1.	0.7	10
14	Missing diversity in brain tumor trials. Neuro-Oncology Advances, 2020, 2, vdaa059.	0.4	9
15	Combined targeting of PI3K and MEK effector pathways via CED for DIPG therapy. Neuro-Oncology Advances, 2019, 1, vdz004.	0.4	8
16	Longitudinal Monitoring of Gd-DTPA Following Convection Enhanced Delivery in the Brainstem. World Neurosurgery, 2020, 137, 38-42.	0.7	8
17	Syringomyelia Resolution Following Chiari Surgery: A Novel Scale for Communication and Research. Neurosurgery, 2021, 88, E60-E66.	0.6	7
18	Outcomes of stereotactic radiosurgery for large vestibular schwannomas: a systematic review and meta-analysis. Neuro-Oncology Practice, 2021, 8, 405-416.	1.0	6

#	ARTICLE	IF	CITATIONS
19	The World of Neurosurgery Reimagined Post COVID-19: Crisis â†” Opportunities. <i>World Neurosurgery</i> , 2021, 148, 251-255.	0.7	6
20	Long-term tumor control after endoscopic endonasal resection of craniopharyngiomas: comparison of gross-total resection versus subtotal resection with radiation therapy. <i>Journal of Neurosurgery</i> , 2022, 136, 1347-1355.	0.9	6
21	Foundations of the Diagnosis and Surgical Treatment of Epilepsy. <i>World Neurosurgery</i> , 2020, 139, 750-761.	0.7	5
22	Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan. <i>CNS Oncology</i> , 2022, 11, .	1.2	4
23	Efficacy and comorbidities of hypofractionated and single-dose radiosurgery for vestibular schwannomas: a systematic review and meta-analysis. <i>Neuro-Oncology Practice</i> , 2021, 8, 391-404.	1.0	3
24	Assessing the long-term safety and efficacy of gamma knife and linear accelerator radiosurgery for vestibular schwannoma: A systematic review and meta-analysis. <i>Neuro-Oncology Practice</i> , 2021, 8, 639-651.	1.0	2
25	Distinct patterns of dentate gyrus cell activation distinguish physiologic from aberrant stimuli. <i>PLoS ONE</i> , 2020, 15, e0232241.	1.1	1
26	EXTH-55. PET, IMAGE-GUIDED HDAC INHIBITION OF PEDIATRIC DIFFUSE MIDLINE GLIOMA IMPROVES SURVIVAL IN MURINE MODELS. <i>Neuro-Oncology</i> , 2020, 22, ii99-ii99.	0.6	1
27	Utility of multimodality molecular profiling for pediatric patients with central nervous system tumors. <i>Neuro-Oncology Advances</i> , 2022, 4, vdac031.	0.4	1
28	DIPG-20. THE DEVELOPMENT OF THERANOSTIC [18F]F2B-CONJUGATES FOR PHARMACOKINETIC MONITORING OF DIRECT DRUG DELIVERY. <i>Neuro-Oncology</i> , 2017, 19, iv9-iv9.	0.6	0
29	TRTH-04. POTENTIAL OF NANO-FIBER PEPTIDE (NFP)-CONJUGATED THERAPEUTICS FOR LOCAL CONVECTION-ENHANCED DELIVERY (CED) IN CNS TUMORS. <i>Neuro-Oncology</i> , 2017, 19, iv52-iv52.	0.6	0
30	DIPG-03. PRE-CLINICAL EVALUATION OF ANDROGEN RECEPTOR AND AROMATASE AS THERAPEUTIC TARGETS IN DIFFUSE INTRINSIC PONTINE GLIOMA. <i>Neuro-Oncology</i> , 2017, 19, iv5-iv5.	0.6	0
31	PDTM-47. REAL TIME IN VIVO MONITORING OF 18F-LABELED PANOBINOSTAT PHARMACOKINETICS FOR TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) VIA CONVECTION ENHANCED DELIVERY (CED). <i>Neuro-Oncology</i> , 2018, 20, vi213-vi214.	0.6	0
32	PDTM-26. DUAL THERAPY WITH PI3K INHIBITOR ZSTK-474 AND MEK INHIBITOR TRAMETINIB VIA CONVECTION-ENHANCED DELIVERY IN A GENETICALLY-ENGINEERED MOUSE MODEL OF DIFFUSE INTRINSIC PONTINE GLIOMA. <i>Neuro-Oncology</i> , 2018, 20, vi209-vi209.	0.6	0
33	BSTM-02. LONGITUDINAL MONITORING OF GD-DTPA FOLLOWING CONVECTION ENHANCED DELIVERY IN THE BRAIN STEM. <i>Neuro-Oncology</i> , 2019, 21, ii67-ii67.	0.6	0
34	RADT-16. HYPOFRACTIONATED RADIOTHERAPY AND STEREOTACTIC RADIOSURGERY FOR VESTIBULAR SCHWANNOMAS: A SYSTEMATIC REVIEW AND META-ANALYSIS. <i>Neuro-Oncology</i> , 2020, 22, ii184-ii185.	0.6	0
35	NCOG-12. STEREOTACTIC RADIOSURGERY FOR VESTIBULAR SCHWANNOMAS IN NEUROFIBROMATOSIS TYPE 2 PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS. <i>Neuro-Oncology</i> , 2020, 22, ii131-ii132.	0.6	0